ARCT

Arcturus Therapeutics Holdings Inc

Oct 13 • 04:00PM ET

19.39

+0.44 2.32 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX PFE NVAX DVAX INO VXRT ALT ADMA ADAP

| Held by: ARKG VTI IWM XBI VXF IBB IWN SCHA VTWO IWO

Index	RUT	P/E	-	EPS (ttm)	-2.22	Insider Own	8.44%	Shs Outstand	27.15M	Perf Week	-7.71%
Market Cap	526.53M	Forward P/E	-	EPS next Y	-2.43	Insider Trans	0.00%	Shs Float	24.86M	Perf Month	11.95%
Enterprise Value	302.02M	PEG	-	EPS next Q	-0.83	Inst Own	95.20%	Short Float	20.69%	Perf Quarter	47.45%
Income	-60.16M	P/S	4.80	EPS this Y	14.81%	Inst Trans	-2.47%	Short Ratio	7.73	Perf Half Y	99.90%
Sales	109.80M	P/B	2.28	EPS next Y	5.06%	ROA	-17.24%	Short Interest	5.14M	Perf YTD	14.26%
Book/sh	8.51	P/C	2.09	EPS next 5Y	56.02%	ROE	-24.57%	52W High	23.59 -17.82%	Perf Year	-11.42%
Cash/sh	9.26	P/FCF	-	EPS past 3/5Y	27.10% -6.84%	ROIC	-23.69%	52W Low	8.04 141.17%	Perf 3Y	20.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	123.72% 46.10%	Gross Margin	96.98%	Volatility	7.94% 8.48%	Perf 5Y	-58.88%
Dividend TTM	-	EV/Sales	2.75	EPS Y/Y TTM	13.41%	Oper. Margin	-43.57%	ATR (14)	1.62	Perf 10Y	-51.32%
Dividend Ex-Date	-	Quick Ratio	5.90	Sales Y/Y TTM	-26.88%	Profit Margin	-54.79%	RSI (14)	49.68	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.90	EPS Q/Q	46.99%	SMA20	-3.84%	Beta	2.48	Target Price	64.78
Payout	-	Debt/Eq	0.12	Sales Q/Q	-46.69%	SMA50	7.90%	Rel Volume	0.90	Prev Close	18.95
Employees	176	LT Debt/Eq	0.10	Earnings	Aug 11 AMC	SMA200	29.99%	Avg Volume	664.99K	Price	19.39
IPO	May 22, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	61.87% 50.28%	Trades		Volume	599,252	Change	2.32%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-25	Resumed	H.C. Wainwright	Buy	$60
May-28-25	Initiated	Scotiabank	Sector Outperform	$32
Jan-28-25	Initiated	BTIG Research	Buy	$41
Aug-12-24	Initiated	Leerink Partners	Outperform	$70
Dec-13-23	Initiated	Canaccord Genuity	Buy	$90
Jul-24-23	Initiated	William Blair	Outperform	$71
May-11-23	Upgrade	H.C. Wainwright	Neutral → Buy	$19 → $51
Nov-14-22	Resumed	Wells Fargo	Overweight	$35
Nov-10-22	Downgrade	Robert W. Baird	Neutral → Underperform	$18
Nov-03-22	Upgrade	Citigroup	Neutral → Buy	$22 → $35
Nov-02-22	Upgrade	Barclays	Underweight → Equal Weight	$16 → $25
Aug-10-22	Downgrade	Raymond James	Mkt Perform → Underperform
Jul-19-22	Resumed	Cantor Fitzgerald	Overweight	$86 → $39
May-11-22	Upgrade	Robert W. Baird	Underperform → Neutral	$21 → $18
Apr-21-22	Downgrade	Citigroup	Buy → Neutral	$86 → $29
Jan-31-22	Upgrade	Raymond James	Underperform → Mkt Perform
Aug-12-21	Downgrade	Raymond James	Mkt Perform → Underperform
Aug-11-21	Downgrade	Goldman	Neutral → Sell	$29
Aug-10-21	Downgrade	Robert W. Baird	Neutral → Underperform	$31
Jul-02-21	Initiated	Cantor Fitzgerald	Overweight	$71

Show Previous Ratings

Oct-03-25 09:51AM	Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Sep-19-25 08:31AM	Cathie Wood Snaps Up $49 Million in This Little-Known Sports Company (GuruFocus.com)
06:50AM	Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire)
Sep-01-25 09:55AM	Should You Buy Arcturus Therapeutics (ARCT) After Golden Cross? (Zacks)
04:01PM	Loading…
Aug-26-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Aug-11-25 06:55PM	Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +30.73%
05:53PM	Arcturus Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress (Business Wire)
Aug-08-25 05:30PM	Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
09:26AM	What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q2 2025 Earnings (GuruFocus.com)
Aug-07-25 08:20AM	Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-05-25 08:15AM	Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-24-25 04:01PM	Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 (Business Wire)
Jul-23-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire) +6.33%
11:00AM	Loading…
Jun-30-25 11:00AM	Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program (Business Wire)
Jun-23-25 08:30AM	Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
Jun-03-25 09:55AM	Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet (Zacks)
May-29-25 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire) +7.70%
May-15-25 09:55AM	Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade (Zacks) +7.38%
May-13-25 08:44AM	Q1 2025 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:10AM	Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ... (GuruFocus.com)
May-12-25 05:10PM	Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.56%
04:08PM	Arcturus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress (Business Wire)
May-09-25 09:39AM	Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Reports Q1 2025 Result (GuruFocus.com)
May-05-25 10:00AM	Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline (Zacks) -7.09%
Apr-22-25 04:01PM	Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 (Business Wire) +10.64%
Apr-11-25 11:49AM	Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate (Zacks)
Apr-10-25 08:00AM	Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 (Business Wire)
04:36PM	Loading…
Mar-20-25 04:36PM	Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
Mar-07-25 11:16AM	Q4 2024 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -8.89%
02:17AM	Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... (GuruFocus.com)
Mar-06-25 05:15PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Arcturus Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress (Business Wire)
Mar-05-25 04:30PM	Arcturus Therapeutics to Present at Leerinks Global Healthcare Conference 2025 (Business Wire)
07:21AM	Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Feb-24-25 04:01PM	Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 (Business Wire) -6.08%
Feb-14-25 08:30AM	European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE, the First Self-amplifying mRNA COVID-19 Vaccine (PR Newswire) +9.99%
Feb-04-25 08:30AM	Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate (Business Wire)
Jan-31-25 03:00AM	Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE, a Self-amplifying mRNA Vaccine Against COVID-19 (Business Wire)
Jan-30-25 04:01PM	Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference (Business Wire)
Jan-10-25 11:14AM	Arcturus Therapeutics launches Phase I Avian Influenza trials in US (Clinical Trials Arena) -5.12%
08:00AM	Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial (Business Wire)
Jan-06-25 04:01PM	Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency (Business Wire) +6.30% +9.23%
Dec-16-24 04:01PM	Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.64%
Dec-11-24 11:55AM	Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers (Insider Monkey)
Nov-26-24 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor Conferences (Business Wire)
Nov-18-24 08:00PM	Arcturus Therapeutics to Present at Jefferies London Healthcare Conference (Business Wire) +11.00%
Nov-14-24 01:00AM	Meiji Seika Pharma Announces Investment in ARCALIS, Inc. (Business Wire)
Nov-11-24 04:01PM	Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial (Business Wire)
Nov-08-24 12:15PM	Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
02:29AM	Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ... (GuruFocus.com)
Nov-07-24 05:55PM	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:48PM	Arcturus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress (Business Wire)
Nov-06-24 07:35AM	Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-31-24 04:01PM	Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024 (Business Wire)
Oct-30-24 12:00PM	Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Oct-23-24 04:00AM	A slow start for self-amplifying mRNA vaccines (Pharmaceutical Technology)
Sep-30-24 11:12AM	Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses (Benzinga) +5.36%
08:00AM	Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination (PR Newswire)
Sep-13-24 08:15AM	Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma (PR Newswire)
Sep-08-24 04:51PM	Arcturus Therapeutics Holdings Inc. (ARCT): Among the Worst ARK Stocks According to Short Sellers (Insider Monkey)
11:49AM	10 Worst ARK Stocks To Buy According To Short Sellers (Insider Monkey)
Sep-03-24 08:30AM	Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis (Business Wire) -8.10%
Sep-02-24 09:55AM	Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect? (Zacks)
Aug-27-24 05:00PM	Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences (Business Wire)
Aug-23-24 12:00PM	What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock (Zacks)
Aug-05-24 08:59PM	ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:10PM	Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Arcturus Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress (Business Wire)
Aug-01-24 04:01PM	Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference (Business Wire) -8.01%
Jul-18-24 07:30PM	Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024 (Business Wire)
Jul-01-24 04:01PM	Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs (Business Wire) -9.21%
Jun-20-24 08:00AM	Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors (Business Wire)
Jun-15-24 02:49AM	Insider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT) (GuruFocus.com)
Jun-07-24 10:30AM	Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference (Business Wire) -25.31%
Jun-04-24 07:00PM	Insider Sale: Chief Scientific Officer & COO Pad Chivukula Sells 26,000 Shares of Arcturus ... (GuruFocus.com) +7.17%
May-28-24 06:30AM	Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program (Business Wire) +26.31%
May-22-24 07:00AM	Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines (GlobeNewswire) +8.48%
May-20-24 08:30AM	Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine (PR Newswire)
May-15-24 04:01PM	Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences (Business Wire) +5.12%
May-09-24 11:13AM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:48AM	Arcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ... (GuruFocus.com)
May-08-24 09:58PM	ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:43PM	Arcturus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress (Business Wire)
May-01-24 10:01AM	Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for (Zacks) +9.15%
Apr-25-24 04:01PM	Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 (Business Wire)
Mar-28-24 01:34AM	Arcturus Therapeutics Holdings Inc (ARCT) Insider Sells Shares (GuruFocus.com)
Mar-22-24 01:26AM	Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ... (GuruFocus.com)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Mar-08-24 12:10PM	Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:54AM	Q4 2023 Arcturus Therapeutics Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:42PM	Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments (GuruFocus.com)
05:10PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:21PM	Arcturus Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chivukula Pad	Chief Scientific Officer & COO	Oct 15 '24	Sale	20.76	12,000	249,121	435,334	Oct 16 09:05 PM
Chivukula Pad	Officer	Oct 15 '24	Proposed Sale	20.76	12,000	249,121		Oct 15 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARCT

Arcturus Therapeutics Holdings Inc

Upgrade your FINVIZ experience